Jeske van Pamelen

A two year clinical, immunological and gut-brain-axis prospective study to predict treatment response to cladribine tablets in relapsing-remitting multiple sclerosis

19 de October de 2026 by Jeske van Pamelen

IntroductionIn relapsing-remitting multiple sclerosis (RRMS) it is challenging to predict which person will benefit from a certain therapy, such as cladribine tablets (CladT). This study aimed to obtain a better understanding of the interaction between…

The gut-brain-axis one year after treatment with cladribine tablets in patients with relapsing remitting multiple sclerosis: a pilot study

27 de February de 2025 by Jeske van Pamelen

IntroductionCladribine tablets are an effective treatment for relapsing remitting multiple sclerosis (RRMS). However, almost half of the treated patients are not free of disease activity after two years. The aim of this study was to describe the change…